Figure 3
From: A glucagon analogue decreases body weight in mice via signalling in the liver
GCG104 reduces body weight in mice by hepatocyte signalling. (a) Fat:lean mass ratio of the hKO mice and controls (n = 13 per group; unpaired t test). (b) Baseline and 15-min glucose response readings for an IPGTT in the hKO (n = 8) and control mice (n = 5; two-way ANOVA with Sidak post hoc test). (c) 12-day cumulative food intake for control and hKO animals injected daily with vehicle (n = 4 and 7, respectively) or 10 nmol/kg GCG104 (n = 5 and 7, respectively; two-way ANOVA with Sidak post hoc test). (d) 12-day cumulative body weight change in control and hKO animals injected daily with vehicle (n = 4 and 7, respectively) or 10 nmol/kg GCG104 (n = 5 and 7, respectively; repeated measures 2-way ANOVA with Tukey’s post hoc test). (e) 12-day change in body composition for control and hKO animals dosed with vehicle (n = 4 and 7, respectively) or 10 nmol/kg GCG104 (n = 5 and 7, respectively); two-way ANOVA with Sidak post hoc test. p values indicated by *p < 0.05, **p < 0.01, ****p < 0.0001. All data presented as mean ± SEM.
